Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

MLA

Klamova, H., et al. “Dasatinib in Imatinib-Resistant or -Intolerant CML Patients: Data from the Clinical Practice of 6 Hematological Centers in the Czech Republic.” Neoplasma, vol. 57, no. 4, 2010, pp. 355–59. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=20429627&authtype=sso&custid=ns315887.

APA

Klamova, H., Faber, E., Zackova, D., Markova, M., Voglova, J., Cmunt, E., Novakova, L., Machova-Polakova, K., Moravcova, J., Dvorakova, D., Michalova, K., Brezinova, J., Oltova, A., Jarosova, M., Cetkovsky, P., Indrak, K., & Mayer, J. (2010). Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma, 57(4), 355–359.

Chicago

Klamova, H, E Faber, D Zackova, M Markova, J Voglova, E Cmunt, L Novakova, et al. 2010. “Dasatinib in Imatinib-Resistant or -Intolerant CML Patients: Data from the Clinical Practice of 6 Hematological Centers in the Czech Republic.” Neoplasma 57 (4): 355–59. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=20429627&authtype=sso&custid=ns315887.